subject: Foreign Competition For China To Accelerate R & D Cancer Drug Market Grab High Ground - Cancer [print this page] Fast-growing oncology market in China is causing a high degree of importance of transnational corporations. Recently, in the United States held the 44th American Society of Clinical Oncology annual meeting, from China's oncology medical specialists for a clinical trial and received global praise of cancer of the medical profession.
The trial is the first time in the field of cancer drug development in China and the Asia Pacific region as the main target of international clinical treatment of liver cancer drug research, the study confirmed: kinase inhibitors sorafenib (Nexavar) may also act on tumor cells and blood vessels, slow the disease process, so the overall survival of patients with advanced hepatocellular carcinoma 47.3% of extending.
The study is the second annual meeting of American Society of Clinical Oncology published the most exciting New Drugs One of R & D progress.
Support the study of tumor treatment institutions Bayer Global CEO Mr. Rosen the exclusive interview that the cancer drug market in China has great potential for China and the Asia Pacific group specializing in clinical trials, Nexavar is the first medication the future will take into account a range of new drugs to patients in China, and if necessary, should carry out special clinical trials.
As the current global cancer community's most influential event in American Society of Clinical Oncology this year from China, is very strong on the one hand, China's growing cancer industry experts were invited to attend the meeting, on the other hand, Almost all of the multinational companies will be looking closely fixed on the Chinese market.
Market cumulative heat WHO recently released data show that China has become the world's second largest high incidence of cancer, China added 2.2 million cancer patients each year, accounting for about 20% of the total number of cancer patients. One in particular, liver, stomach and lung cancer as a major health menace.
"The world's liver cancer patients accounted for half of China." Guangdong Zhongshan University Cancer Center, Professor Zhong-Zhen Guan of China to the reporters about the incidence of cancer of the latest: Hepatocellular carcinoma is the most common liver cancer, accounting for adult primary malignant liver tumors Jiucheng. Liver cancer is the sixth most common cancer, each year more than 60 million cases of new hair. Including China, Korea, Japan, and about 400,000 cases of China Taiwan, Europe, the United States approximately 60,000 cases, and the incidence is increasing. At present, China and the Asia Pacific region continued to increase the incidence of liver cancer, mainly due to chronic hepatitis B Hepatitis HIV infection rate, the whole region, about 200 million people infected.
Potential anticancer drug market in China has aroused great interest from domestic and foreign pharmaceutical companies, antitumor drugs in China in recent years has become the fastest growing areas of segments. It's knowledge, the world's major multinational pharmaceutical companies are competing to be the latest listing of anticancer drug in China, according to data from the U.S. pharmaceutical manufacturers association, the existing 178 companies of about 400 cancer drugs in clinical trials This is in the Development of Alzheimer's disease and depression drugs, 2 times, almost the development of heart disease and stroke treatments 3 times. In addition, the world's major transnational giant tumor drug market monopoly situation is relatively clear. They are accelerating the introduction of new drugs to the Chinese market. In 2006, received FDA approval in 3 months, Bayer Nexavar quickly introduced into China, hoping to intervene in the competitive strength of Chinese anti-cancer drug market. It is reported that Nexavar treatment of hepatocellular carcinoma of new indications pending.
The other hand, domestic Pharmaceutical Industry Are not willing to campaign only in the field of generic drugs. First Sign of medicine in 2006 spent 200 million yuan acquisition of Tianjin, Yantai wheat was 80% of the shares of biotechnology companies, the main intention is that the company has successfully developed anti-tumor drug, "En degree" in the bag, but also further widen the domestic enterprises new drugs through to meddle in the field of cancer drug market, competing for the prelude.
Seize the high ground of R & D
The 44th American Society of Clinical Oncology meeting, many international cancer community experts have expressed the future development of the latest cancer drugs, anticancer drugs will follow the chemotherapy drugs, anti-angiogenic drugs, genes and targeted drug forward direction. Competitive advantage in the future will focus on those genes and targeted drug breakthrough products.
Oncology, Bayer HealthCare senior vice president of global strategic market for what? Rosen said after the R & D over the past 15 years to accumulate, the current cancer drug discovery in the kinase inhibition Preparation In the field has come to harvest. Nexavar has become difficult to treat liver cancer in the first widely approved new therapy.
Learned that Bayer oncology product system including multi-kinase inhibition Preparation , One has to stop most of the uncontrolled tumor cell replication and angiogenesis (the formation of blood supply) the potential of therapeutic products,. By interfering with the kinase (to tumor growth and spread of the signal transduction protein), multi-kinase inhibitors can prevent cancer cell proliferation and self-nutrition supplies for his death. These agents can inhibit tumor growth potential and contribute to the cancer into a chronic controllable disease. It is located in Berlin, Germany, Bayer has 60 laboratories worldwide oncology research centers, more than 300 years of biochemistry expert effort.
